Human papillomavirus 16 and 18 L1 serology in Korean women with high-grade cervical intraepithelial neoplasia and cervical cancer

Nan H. Jeong, Mi Kyung Woo, Nak Woo Lee, Sook J. Hur, Kum Sook Choi, Hong J. Kim

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

We aimed to determine the prevalence of HPV-16/18 antibodies in Korean women with high-grade cervical intraepithelial neoplasia (CIN) and cervical cancer. We conducted the hospital-based case-control study at the university hospital between 2003 and 2006. Cases were 130 high-grade CIN and 43 cervical cancer patients and the control group was 106 women showing normal cervical cytology. Enzyme-linked immunosorbent assays were performed for HPV-16/18 L1 virus-like particles (VLPs) as an antigen. Seropositivity for HPV-16 VLP and HPV-18 VLP was found in 67.4% and 30.2% of cancer patients and 59.2% and 20.0% of high-grade CIN patients, respectively. Seropositivity for HPV-16 with high-grade CIN (OR 6.91; 95% CI 3.74-12.76) and cervical cancer (OR 8.99; 95% CI 3.88-20.84) presented significant associations, as did seropositivity for HPV-18 (high-grade CIN: OR 3.64; 95% CI 1.67-7.95, cervical cancer: OR 6.82; 95% CI 2.52-18.45). Patients with both HPV-16 and 18 seropositivity were 9.38 times (95% CI 2.98-29.51) more likely to have high-grade CIN and 17.05 times (95% CI 4.55-63.87) more likely to have cancer. Both HPV 16 and 18 L1 VLP serology is the clear disease predictors of presence of high-grade CIN and cervical cancer.

Original languageEnglish
Pages (from-to)1013-1018
Number of pages6
JournalArchives of Pharmacal Research
Volume32
Issue number7
DOIs
Publication statusPublished - 2009 Jul 1

Fingerprint

Human papillomavirus 18
Cervical Intraepithelial Neoplasia
Human papillomavirus 16
Serology
Viruses
Uterine Cervical Neoplasms
Virion
Cytology
Immunosorbents
Assays
Antigens
Antibodies
Enzymes
Cell Biology
Case-Control Studies
Neoplasms
Enzyme-Linked Immunosorbent Assay
Control Groups

Keywords

  • Cervical cancer
  • Cervical intraepithelial neoplasia
  • Enzyme-linked immunosorbent assay
  • Human papillomavirus
  • Serology
  • Virus-like particles

ASJC Scopus subject areas

  • Molecular Medicine
  • Organic Chemistry
  • Drug Discovery

Cite this

Human papillomavirus 16 and 18 L1 serology in Korean women with high-grade cervical intraepithelial neoplasia and cervical cancer. / Jeong, Nan H.; Woo, Mi Kyung; Lee, Nak Woo; Hur, Sook J.; Choi, Kum Sook; Kim, Hong J.

In: Archives of Pharmacal Research, Vol. 32, No. 7, 01.07.2009, p. 1013-1018.

Research output: Contribution to journalArticle

Jeong, Nan H. ; Woo, Mi Kyung ; Lee, Nak Woo ; Hur, Sook J. ; Choi, Kum Sook ; Kim, Hong J. / Human papillomavirus 16 and 18 L1 serology in Korean women with high-grade cervical intraepithelial neoplasia and cervical cancer. In: Archives of Pharmacal Research. 2009 ; Vol. 32, No. 7. pp. 1013-1018.
@article{f1d0713e972a4721be176726f2f1f302,
title = "Human papillomavirus 16 and 18 L1 serology in Korean women with high-grade cervical intraepithelial neoplasia and cervical cancer",
abstract = "We aimed to determine the prevalence of HPV-16/18 antibodies in Korean women with high-grade cervical intraepithelial neoplasia (CIN) and cervical cancer. We conducted the hospital-based case-control study at the university hospital between 2003 and 2006. Cases were 130 high-grade CIN and 43 cervical cancer patients and the control group was 106 women showing normal cervical cytology. Enzyme-linked immunosorbent assays were performed for HPV-16/18 L1 virus-like particles (VLPs) as an antigen. Seropositivity for HPV-16 VLP and HPV-18 VLP was found in 67.4{\%} and 30.2{\%} of cancer patients and 59.2{\%} and 20.0{\%} of high-grade CIN patients, respectively. Seropositivity for HPV-16 with high-grade CIN (OR 6.91; 95{\%} CI 3.74-12.76) and cervical cancer (OR 8.99; 95{\%} CI 3.88-20.84) presented significant associations, as did seropositivity for HPV-18 (high-grade CIN: OR 3.64; 95{\%} CI 1.67-7.95, cervical cancer: OR 6.82; 95{\%} CI 2.52-18.45). Patients with both HPV-16 and 18 seropositivity were 9.38 times (95{\%} CI 2.98-29.51) more likely to have high-grade CIN and 17.05 times (95{\%} CI 4.55-63.87) more likely to have cancer. Both HPV 16 and 18 L1 VLP serology is the clear disease predictors of presence of high-grade CIN and cervical cancer.",
keywords = "Cervical cancer, Cervical intraepithelial neoplasia, Enzyme-linked immunosorbent assay, Human papillomavirus, Serology, Virus-like particles",
author = "Jeong, {Nan H.} and Woo, {Mi Kyung} and Lee, {Nak Woo} and Hur, {Sook J.} and Choi, {Kum Sook} and Kim, {Hong J.}",
year = "2009",
month = "7",
day = "1",
doi = "10.1007/s12272-009-1706-z",
language = "English",
volume = "32",
pages = "1013--1018",
journal = "Archives of Pharmacal Research",
issn = "0253-6269",
publisher = "Pharmaceutical Society of Korea",
number = "7",

}

TY - JOUR

T1 - Human papillomavirus 16 and 18 L1 serology in Korean women with high-grade cervical intraepithelial neoplasia and cervical cancer

AU - Jeong, Nan H.

AU - Woo, Mi Kyung

AU - Lee, Nak Woo

AU - Hur, Sook J.

AU - Choi, Kum Sook

AU - Kim, Hong J.

PY - 2009/7/1

Y1 - 2009/7/1

N2 - We aimed to determine the prevalence of HPV-16/18 antibodies in Korean women with high-grade cervical intraepithelial neoplasia (CIN) and cervical cancer. We conducted the hospital-based case-control study at the university hospital between 2003 and 2006. Cases were 130 high-grade CIN and 43 cervical cancer patients and the control group was 106 women showing normal cervical cytology. Enzyme-linked immunosorbent assays were performed for HPV-16/18 L1 virus-like particles (VLPs) as an antigen. Seropositivity for HPV-16 VLP and HPV-18 VLP was found in 67.4% and 30.2% of cancer patients and 59.2% and 20.0% of high-grade CIN patients, respectively. Seropositivity for HPV-16 with high-grade CIN (OR 6.91; 95% CI 3.74-12.76) and cervical cancer (OR 8.99; 95% CI 3.88-20.84) presented significant associations, as did seropositivity for HPV-18 (high-grade CIN: OR 3.64; 95% CI 1.67-7.95, cervical cancer: OR 6.82; 95% CI 2.52-18.45). Patients with both HPV-16 and 18 seropositivity were 9.38 times (95% CI 2.98-29.51) more likely to have high-grade CIN and 17.05 times (95% CI 4.55-63.87) more likely to have cancer. Both HPV 16 and 18 L1 VLP serology is the clear disease predictors of presence of high-grade CIN and cervical cancer.

AB - We aimed to determine the prevalence of HPV-16/18 antibodies in Korean women with high-grade cervical intraepithelial neoplasia (CIN) and cervical cancer. We conducted the hospital-based case-control study at the university hospital between 2003 and 2006. Cases were 130 high-grade CIN and 43 cervical cancer patients and the control group was 106 women showing normal cervical cytology. Enzyme-linked immunosorbent assays were performed for HPV-16/18 L1 virus-like particles (VLPs) as an antigen. Seropositivity for HPV-16 VLP and HPV-18 VLP was found in 67.4% and 30.2% of cancer patients and 59.2% and 20.0% of high-grade CIN patients, respectively. Seropositivity for HPV-16 with high-grade CIN (OR 6.91; 95% CI 3.74-12.76) and cervical cancer (OR 8.99; 95% CI 3.88-20.84) presented significant associations, as did seropositivity for HPV-18 (high-grade CIN: OR 3.64; 95% CI 1.67-7.95, cervical cancer: OR 6.82; 95% CI 2.52-18.45). Patients with both HPV-16 and 18 seropositivity were 9.38 times (95% CI 2.98-29.51) more likely to have high-grade CIN and 17.05 times (95% CI 4.55-63.87) more likely to have cancer. Both HPV 16 and 18 L1 VLP serology is the clear disease predictors of presence of high-grade CIN and cervical cancer.

KW - Cervical cancer

KW - Cervical intraepithelial neoplasia

KW - Enzyme-linked immunosorbent assay

KW - Human papillomavirus

KW - Serology

KW - Virus-like particles

UR - http://www.scopus.com/inward/record.url?scp=68649101473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68649101473&partnerID=8YFLogxK

U2 - 10.1007/s12272-009-1706-z

DO - 10.1007/s12272-009-1706-z

M3 - Article

C2 - 19641882

AN - SCOPUS:68649101473

VL - 32

SP - 1013

EP - 1018

JO - Archives of Pharmacal Research

JF - Archives of Pharmacal Research

SN - 0253-6269

IS - 7

ER -